FEBS Journal 2015-03-01

Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases.

Hanna-Kirsti S Leiros, Kine Susann Waade Edvardsen, Gro Elin Kjaereng Bjerga, Ørjan Samuelsen

Index: FEBS J. 282(6) , 1031-42, (2015)

Full Text: HTML

Abstract

During the last decades antimicrobial resistance has become a global health problem. Metallo-β-lactamases (MBLs) which are broad-spectrum β-lactamases that inactivate virtually all β-lactams including carbapenems, are contributing to this health problem. In this study a novel MBL variant, termed VIM-26, identified in a Klebsiella pneumoniae isolate was studied. VIM-26 belongs to the Verona integron-encoded metallo-β-lactamase (VIM) family of MBLs and is a His224Leu variant of the well-characterized VIM-1 variant. In this study, we report the kinetic parameters, minimum inhibitory concentrations and crystal structures of a recombinant VIM-26 protein, and compare them to previously published data on VIM-1, VIM-2 and VIM-7. The kinetic parameters and minimum inhibitory concentration determinations show that VIM-26, like VIM-7, has higher penicillinase activity but lower cephalosporinase activity than VIM-1 and VIM-2. The four determined VIM-26 crystal structures revealed mono- and di-zinc forms, where the Zn1 ion has distorted tetrahedral coordination geometry with an additional water molecule (W2) at a distance of 2.6-3.7 Å, which could be important during catalysis. The R2 drug binding site in VIM-26 is more open compared to VIM-2 and VIM-7 and neutrally charged due to Leu224 and Ser228. Thus, the VIM-26 drug binding properties are different from the VIM-2 (Tyr224/Arg228) and VIM-7 (His224/Arg228) structures, indicating a role of these residues in the substrate specificity. © 2015 FEBS.


Related Compounds

  • HEPES
  • Cefuroxime
  • Ampicillin Trihyd...
  • Ampicillin
  • Ceftazidime Penta...
  • Meropenem trihydra...

Related Articles:

Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth.

2014-01-01

[PLoS Biol. 12(1) , e1001758, (2014)]

Functional consequence of the MET-T1010I polymorphism in breast cancer.

2015-02-20

[Oncotarget 6(5) , 2604-14, (2015)]

Immunomodulation by the Pseudomonas syringae HopZ type III effector family in Arabidopsis.

2014-01-01

[PLoS ONE 9(12) , e116152, (2014)]

Aptamer-based polyvalent ligands for regulated cell attachment on the hydrogel surface.

2015-04-13

[Biomacromolecules 16(4) , 1382-9, (2015)]

Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy.

2015-05-01

[Biomaterials 51 , 1-11, (2015)]

More Articles...